TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarkerErica L. Mayer, Eric P. Winer, Rachel C. Jankowitz et al.|Annals of Oncology|2020Cited by 81